Home > Healthcare > Biotechnology > Biopharma > Gene Vector Market

Gene Vector Market Trends

Report ID: GMI5693
Published Date: May 2023
Report Format: PDF

Download Free Sample

Gene Vector Market Trends

Gene vector industry revenue growth is driven by factors such as rising prevalence of genetic disorders, cancer, and infectious diseases, development of more advanced gene editing technologies, and increasing demand for personalized medicine. Gene vectors are necessary for the delivery of gene treatments into target cells in many instances of gene therapy, with viral vectors being among the most extensively studied vectors owing to their unique benefits, such as their exceptional transduction efficiency.

Various products using viral vectors to deliver therapeutic genes have been approved for use against cancer, infectious diseases, and monogenic disorders. Also, several clinical tests are currently being conducted to increase their therapeutic utility. Gene delivery methods rely on retrovirus, Adenovirus (Ad), poxvirus, Herpes Simplex Virus (HSV), and Adeno-Associated Virus (AAV) has been employed in over 66% of all gene therapy clinical trials to date. These viruses were initially used to build gene delivery systems because they are easily controlled in vitro and have been extensively investigated. Numerous characteristics of these viral vectors affect their potential for various therapeutic applications.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market for gene vector crossed USD 1.20 billion in 2022 and will grow at 13.1% CAGR between 2023 and 2032.

Gene vector demand across gene therapy will grow substantially through 2032 due to its increasing use in the treatment of cancer, chronic disease, infectious disease, and blood disorders.

North America gene vector market held 53.8% revenue share in 2022 owing to the presence of a large number of R&D centers and institutes developing advanced gene therapies.

Cobra Biologics, SIRION Biotech, Lonza, Oxford Biomedica, Novasep, Spark Therapeutics, Kaneka Eurogentec, and Brammer Bio are some of the major companies in the market.